ZYME — Zymeworks Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2017-04-28.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ZYME
| date | signal | measured base rate |
|---|---|---|
| 2026-08-21 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-08-05 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-08-03 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-31 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-24 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-06 | Hollywood Mark EVP & Chief Operating Officer | Grant or award | 939 | 22.22 | 20.9K |
| 2026-01-12 | Galbraith Kenneth Chair & CEO | Open-market sale | 30.4K | 22.67 | 689.7K |
| 2026-01-12 | Moore Paul Andrew Chief Scientific Officer | Open-market sale | 9.6K | 22.67 | 216.7K |
| 2026-01-12 | Smith Jeffrey T L EVP & Chief Medical Officer | Open-market sale | 9.3K | 22.67 | 211.1K |
| 2026-01-12 | Hollywood Mark EVP & Chief Operating Officer | Open-market sale | 6.1K | 22.67 | 138.7K |
| 2026-01-12 | Galbraith Kenneth Chair & CEO | Option exercise | 64.0K | 0.00 | 0 |
| 2026-01-12 | Moore Paul Andrew Chief Scientific Officer | Option exercise | 17.7K | 0.00 | 0 |
| 2026-01-12 | Smith Jeffrey T L EVP & Chief Medical Officer | Option exercise | 17.7K | 0.00 | 0 |
| 2026-01-12 | Hollywood Mark EVP & Chief Operating Officer | Option exercise | 17.7K | 0.00 | 0 |
| 2026-01-06 | PATTERSON LEONE D EVP, Chief Bus & Fin Officer | Grant or award | 459 | 10.55 | 4.8K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| EcoR1 Capital, LLC | 575.2M | 23.0M |
| Rubric Capital Management LP | 175.3M | 7.0M |
| BlackRock, Inc. | 114.0M | 4.6M |
| BVF INC/IL | 93.5M | 3.7M |
| PERCEPTIVE ADVISORS LLC | 87.9M | 3.5M |
| MORGAN STANLEY | 62.1M | 2.5M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 47.8M | 1.9M |
| VANGUARD CAPITAL MANAGEMENT LLC | 42.7M | 1.7M |
| CITADEL ADVISORS LLC | 28.8M | 1.2M |
| DIMENSIONAL FUND ADVISORS LP | 28.5M | 1.1M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 10-Q | 2026-08-06 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-06 | 2026-08-06 | on EDGAR ↗ |
| 4 | 2026-07-06 | 2026-07-06 | on EDGAR ↗ |
| 8-K | 2026-06-29 | 2026-06-28 | on EDGAR ↗ |
| 4 | 2026-05-15 | 2026-05-13 | on EDGAR ↗ |
| 3 | 2026-05-15 | 2026-05-13 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-05-15 | — | on EDGAR ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
Ask the AI about ZYME
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →